Pancreatic Cancer Research

ResearcherTokyo Metropolitan Institute of GerontologyActive in the last 2 years

Tomio Arai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4583-8301; OpenAlex author ID A5043840057. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 6 papers · 2019: 4 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 20

  1. Mucin expression in pancreatic ductal adenocarcinoma cell lines in 2D and 3D cultures: A proteomic and immunocytochemical analysis. Co-author DOI 10.1371/journal.pone.0353991↗
  2. Proteomic and immunocytochemical analyses of squamous components in two- and three-dimensional-cultured pancreatic ductal adenocarcinoma cell lines. Co-author DOI 10.3892/ol.2026.15540↗
  3. Transmission electron microscopic analysis of pancreatic ductal adenocarcinoma cell spheres formed in 3D cultures. Co-author DOI 10.1007/s00795-025-00435-1↗
  4. Cytotoxic and senescence-inducing effects of BLU554 in pancreatic ductal adenocarcinoma: an in vitro study. Co-author DOI 10.1186/s12885-025-15317-z↗
  5. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancr… Co-author DOI 10.1016/j.eclinm.2022.101731↗
  6. Rare germline variants in pancreatic cancer and multiple primary cancers: an autopsy study. Co-author DOI 10.1097/cej.0000000000000787↗
  7. Epithelial and Mesenchymal Features of Pancreatic Ductal Adenocarcinoma Cell Lines in Two- and Three-Dimensional Cultures. Co-author DOI 10.3390/jpm12050746↗
  8. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression g… Co-author DOI 10.1038/s41598-020-74067-z↗
  9. Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture. Co-author DOI 10.1038/s41598-019-47416-w↗
  10. Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0222155↗
  11. The stem cell-specific intermediate filament nestin missense variation p.A1199P is associated with pancreatic cancer. Last author DOI 10.3892/ol.2019.10106↗
  12. Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis. Last author DOI 10.3892/ol.2019.10764↗
  13. Pancreatic cancer stem cells: features and detection methods. Co-author DOI 10.1007/s12253-018-0420-x↗
  14. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreati… Co-author DOI 10.1016/j.gie.2017.10.030↗
  15. Reduced expression of the H19 long non-coding RNA inhibits pancreatic cancer metastasis. Co-author DOI 10.1038/s41374-018-0048-1↗
  16. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions. Co-author DOI 10.1111/cas.13533↗
  17. H19 long non-coding RNA contributes to sphere formation and invasion through regulation of CD24 and integrin expression in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.26176↗
  18. Electron microscopic analysis of different cell types in human pancreatic cancer spheres. Co-author DOI 10.3892/ol.2017.7554↗
  19. Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer. Last author DOI 10.1111/cas.13139↗
  20. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis. Last author DOI 10.1097/mpa.0000000000000427↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshiyuki Ishiwata · 15 shared papers, 2016–2026 · strength 2.10
  2. Yuuki Shichi · 6 shared papers, 2019–2026 · strength 1.33
  3. Yoko Matsuda · 14 shared papers, 2016–2023 · strength 1.30
  4. Masakazu Fujiwara · 4 shared papers, 2025–2026 · strength 1.06
  5. Norihiko Sasaki · 7 shared papers, 2018–2022 · strength 0.67
  6. Fujiya Gomi · 3 shared papers, 2019–2025 · strength 0.52
  7. Junko Aida · 6 shared papers, 2018–2019 · strength 0.49
  8. Hisashi Yoshimura · 6 shared papers, 2016–2019 · strength 0.48
  9. Makoto Nishimura · 3 shared papers, 2018–2023 · strength 0.36
  10. Masashi Toyoda · 3 shared papers, 2018–2019 · strength 0.25
  11. Naohisa Yahagi · 2 shared papers, 2018–2023 · strength 0.24
  12. Takao Itoi · 2 shared papers, 2018–2023 · strength 0.24
  13. Hiroo Fujitani · 1 shared paper, 2023 · strength 0.22
  14. Yasushi Okazaki · 1 shared paper, 2023 · strength 0.22
  15. Toshio Fujisawa · 1 shared paper, 2023 · strength 0.16
  16. Hiroyuki Isayama · 1 shared paper, 2023 · strength 0.16
  17. Motohiko Kato · 1 shared paper, 2023 · strength 0.16
  18. Kazuki Takakura · 1 shared paper, 2023 · strength 0.16
  19. Shomei Ryozawa · 1 shared paper, 2023 · strength 0.16
  20. Hideyuki Saya · 1 shared paper, 2023 · strength 0.16
  21. Aya Kawanishi · 1 shared paper, 2020 · strength 0.10
  22. Shinichiro Takahashi · 1 shared paper, 2020 · strength 0.10
  23. Motohiro Kojima · 1 shared paper, 2020 · strength 0.10
  24. Mari A. Mino-Kenudson · 1 shared paper, 2020 · strength 0.10
  25. Kenichi Hirabayashi · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.